$126.22
0.96[0.77%]
At close: Apr 23
$126.22
0[0.00%]
PreMarket: 5:17AM EDT
Novo Nordisk
(NYSE:NVO)Novo Nordisk Stock (NYSE:NVO), Analyst Ratings, Price Targets, Predictions
Novo Nordisk A/S has a consensus price target of $69.08, established from looking at the 24 latest analyst ratings. The last 3 analyst ratings were released from Cantor Fitzgerald, BMO Capital, and Cantor Fitzgerald on April 18, 2024, April 12, 2024, and April 5, 2024. With an average price target of $161 between Cantor Fitzgerald, BMO Capital, and Cantor Fitzgerald, there's an implied 27.56% upside for Novo Nordisk A/S from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Cantor Fitzgerald
BMO Capital
Argus Research
Morgan Stanley
TD Cowen
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Novo Nordisk
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/18/2024 | NVO | Buy Now | Novo Nordisk | $126.22 | 26.76% | Cantor Fitzgerald | Louise Chen | → $160 | Reiterates | Overweight → Overweight | Get Alert |
| 04/12/2024 | NVO | Buy Now | Novo Nordisk | $126.22 | 29.14% | BMO Capital | Evan David Seigerman | → $163 | Initiates | → Outperform | Get Alert |
| 04/05/2024 | NVO | Buy Now | Novo Nordisk | $126.22 | 26.76% | Cantor Fitzgerald | Louise Chen | → $160 | Reiterates | Overweight → Overweight | Get Alert |
| 04/01/2024 | NVO | Buy Now | Novo Nordisk | $126.22 | 26.76% | Cantor Fitzgerald | Louise Chen | → $160 | Reiterates | Overweight → Overweight | Get Alert |
| 03/20/2024 | NVO | Buy Now | Novo Nordisk | $126.22 | 26.76% | Cantor Fitzgerald | Louise Chen | → $160 | Reiterates | Overweight → Overweight | Get Alert |
| 03/08/2024 | NVO | Buy Now | Novo Nordisk | $126.22 | 26.76% | Cantor Fitzgerald | Louise Chen | $140 → $160 | Maintains | Overweight | Get Alert |
| 02/20/2024 | NVO | Buy Now | Novo Nordisk | $126.22 | 10.92% | Cantor Fitzgerald | Louise Chen | → $140 | Reiterates | Overweight → Overweight | Get Alert |
| 02/15/2024 | NVO | Buy Now | Novo Nordisk | $126.22 | 10.92% | Cantor Fitzgerald | Louise Chen | → $140 | Reiterates | Overweight → Overweight | Get Alert |
| 02/14/2024 | NVO | Buy Now | Novo Nordisk | $126.22 | 10.92% | Cantor Fitzgerald | Louise Chen | → $140 | Reiterates | Overweight → Overweight | Get Alert |
| 02/01/2024 | NVO | Buy Now | Novo Nordisk | $126.22 | -0.97% | Argus Research | Jasper Hellweg | $115 → $125 | Maintains | Buy | Get Alert |
| 02/01/2024 | NVO | Buy Now | Novo Nordisk | $126.22 | 10.92% | Cantor Fitzgerald | Louise Chen | $120 → $140 | Maintains | Overweight | Get Alert |
| 01/23/2024 | NVO | Buy Now | Novo Nordisk | $126.22 | -4.93% | Morgan Stanley | Mark Purcell | → $120 | Initiates | → Overweight | Get Alert |
| 12/04/2023 | NVO | Buy Now | Novo Nordisk | $126.22 | -8.89% | TD Cowen | Michael Nedelcovych | $105 → $115 | Maintains | Outperform | Get Alert |
| 12/01/2023 | NVO | Buy Now | Novo Nordisk | $126.22 | -8.89% | Argus Research | John Eade | $110 → $115 | Maintains | Buy | Get Alert |
| 12/01/2023 | NVO | Buy Now | Novo Nordisk | $126.22 | -4.93% | Cantor Fitzgerald | Louise Chen | → $120 | Initiates | → Overweight | Get Alert |
| 10/02/2023 | NVO | Buy Now | Novo Nordisk | $126.22 | -12.85% | Argus Research | John Eade | → $110 | Initiates | → Buy | Get Alert |
| 03/28/2023 | NVO | Buy Now | Novo Nordisk | $126.22 | -75.44% | BTIG | Justin Zelin | $10 → $15.5 | Maintains | Buy | Get Alert |
| 12/12/2022 | NVO | Buy Now | Novo Nordisk | $126.22 | 14.88% | TD Cowen | Michael Nedelcovych | $65 → $72.5 | Maintains | Outperform | Get Alert |
| 06/28/2022 | NVO | Buy Now | Novo Nordisk | $126.22 | — | UBS | Michael Leuchten | — | Downgrade | Neutral → Sell | Get Alert |
FAQ
What is the target price for Novo Nordisk (NVO)?
The latest price target for Novo Nordisk (NYSE: NVO) was reported by Cantor Fitzgerald on April 18, 2024. The analyst firm set a price target for $160.00 expecting NVO to rise to within 12 months (a possible 26.76% upside). 16 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Novo Nordisk (NVO)?
The latest analyst rating for Novo Nordisk (NYSE: NVO) was provided by Cantor Fitzgerald, and Novo Nordisk reiterated their overweight rating.
When was the last upgrade for Novo Nordisk (NVO)?
The last upgrade for Novo Nordisk A/S happened on June 7, 2022 when JP Morgan raised their price target to N/A. JP Morgan previously had a neutral for Novo Nordisk A/S.
When was the last downgrade for Novo Nordisk (NVO)?
The last downgrade for Novo Nordisk A/S happened on June 28, 2022 when UBS changed their price target from N/A to N/A for Novo Nordisk A/S.
When is the next analyst rating going to be posted or updated for Novo Nordisk (NVO)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Novo Nordisk, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Novo Nordisk was filed on April 18, 2024 so you should expect the next rating to be made available sometime around April 18, 2025.
Is the Analyst Rating Novo Nordisk (NVO) correct?
While ratings are subjective and will change, the latest Novo Nordisk (NVO) rating was a reiterated with a price target of $0.00 to $160.00. The current price Novo Nordisk (NVO) is trading at is $126.22, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.